Related news from
Thu, 25 Apr 2024 15:34:24 +0000	20 Fastest Growing Health Tech Companies in the World In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
Thu, 25 Apr 2024 14:02:05 +0000	Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 24 Apr 2024 16:05:00 +0000	Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold? While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Mon, 22 Apr 2024 21:50:17 +0000	Why Amgen (AMGN) Outpaced the Stock Market Today In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.
Mon, 22 Apr 2024 15:10:59 +0000	10 Best Performing Biotech ETFs in 2024 In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
Fri, 19 Apr 2024 11:14:00 +0000	The Dividend Goldmine: 3 Shining Stocks With Growing Payouts There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give investors a means to achieve solid returns and reliable income streams. Three exceptional businesses light up the scene in this domain with their steadfast dedication to growth and shareholder rewards. The first one, a key player in the communication services industry, demonstrates a strategic shift t
Wed, 17 Apr 2024 22:00:17 +0000	Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
Wed, 17 Apr 2024 12:00:00 +0000	Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble When the term blue chip is thrown around, many investors hear synonyms like stability and success. Other definitions limit blue-chip stocks to the 30 companies comprising the Dow Jones Industrial Average. However, blue chip stocks should be considered as those representing long-running and well-established companies that prioritize their financial health. Moreover, these companies typically command a market capitalization numbering in the billions or even trillions of dollars. This ensures both
Wed, 17 Apr 2024 12:00:00 +0000	Coming FDA Approvals Could Send These 3 Drug Stocks Soaring In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug s
Wed, 17 Apr 2024 11:30:00 +0000	Can This High-Yield Dividend Stock Keep Beating the S&P 500? Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Wed, 17 Apr 2024 08:30:00 +0000	Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
Tue, 16 Apr 2024 21:26:00 +0000	AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
Tue, 16 Apr 2024 20:30:00 +0000	The 3 Best Biotech Stocks to Buy Now: Q2 Edition Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities. We’re even seeing big opportunities in cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. We can even look at the impact artificial intelligence could have on he
Mon, 15 Apr 2024 19:07:27 +0000	3 Stocks to Buy Low Today With High Hopes for Tomorrow Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal. However, the challenge lies not only in identifying overvalued and undervalued stocks trading at appreciated or depressed prices but also in those with promising potential.There may be several reasons why undervalued stocks do not reflect their
Mon, 15 Apr 2024 13:07:11 +0000	Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Thu, 11 Apr 2024 22:00:18 +0000	Amgen (AMGN) Laps the Stock Market: Here's Why In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
Thu, 11 Apr 2024 12:00:00 +0000	Is Amgen Stock a Buy? Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
Wed, 10 Apr 2024 13:27:00 +0000	This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
Tue, 09 Apr 2024 11:37:17 +0000	11 Best Biotech ETFs To Buy In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
Tue, 09 Apr 2024 11:00:00 +0000	3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April It’s been a volatile start to the second quarter for many sectors. However, investors continue to seek out undervalued biotech stocks for robust returns over the long term. Plenty of options exist in various niches within the biotech sector. That said, investor focus remains on key sectors, including weight-loss drugs, Parkinson’s treatments and drugs aimed at Alzheimer’s. It’s worth pointing out that biotech stocks are among some of the higher-risk options in the market. These companies’ massiv